The use of erythropoietin in patients undergoing radical prostatectomy: Effects on hematocrit, transfusion rates and quality of life

Urologia Internationalis

Volumn 77, Issue 3, 2006, Pages 211-215

  Gaston, Kris E ^a   Kouba, Erik ^a   Moore, Dominic T ^b,c   Pruthi, Raj S ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Erythropoietin; Prostate cancer; Radical prostatectomy

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FITNESS; HEMATOCRIT; HUMAN; MALE; MENTAL FUNCTION; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 12; UNITED STATES;

ADULT; AGED; BLOOD TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; FOLLOW-UP STUDIES; HEMATOCRIT; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33750003872     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094811     Document Type: Article

References (23)

1. American Cancer Society: Cancer facts and figures 2003. www.cancer.org.
2. Wingo PA, Guest JL, McGinnis L, Miller DS, Rodrigueuz C, Cardinez CJ, Morrow B, Thun MJ: Patterns of inpatient surgeries for the top four cancers in the United States, National Hospital Discharge Survey, 1988-95. Cancer Causes Control 2000;11:497-512.
3. National Cancer Institute: Understanding treatment choices for prostate cancer. Bethesda, Md., USA, National Institutes of Health Publication No 00-4659, 2002.
4. Peter CA, Walsh PC: Blood transfusion and anesthetic practices in radical retropubic prostatectomy. J Urol 1985;134:81-83.
5. Lepor H, Nieder AM, Ferrandino MN: Intraoperative and post-operative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. J Urol 2001;166:1729-1733.
6. Shekarriz B, Upadhyay J, Wood D: Intraoperative, perioperative, and long-term complications of radical prostatectomy. Urol Clin North Am 2001;28:639-653.
7. Stewart AL, Hays RD, Ware JE Jr: The MOS short form general health survey. Reliability and validity in a patient population. Med Care 1988;7:724-735.
8. Rosenblum N, Levine MA, Handler T, Lepor H: The role of preoperative epoetin alfa in men undergoing radical retropubic prostatectomy. J Urol 2000;163:829-833.
9. Sowade O, Warnke H, Scigalla P, Sowade B, Franke W, Messinger D, Gross J: Avoidance of allogenic blood transfusions by treatment with recombinant human erythropoietin in patients undergoing open-heart surgery. Blood 1997;89:411-418.
10. Canadian Orthopedic Perioperative Erythropoietin Study Group: Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993;341:1227-1232.
11. Faris PM, Ritter MA, Abels RI: The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopedic operation. J Bone Joint Surg Am 1996;78:62-72.
12. Eschbach JW, Egrie JC, Downing MR, Browne JR, Adamson JW: Correction of anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-78.
13. Goodnough LT, Andersn KC, Kurtz S: Indications and guidelines for the use of hematopoietic growth factor. Transfusion 1993;33:944-959.
14. Goodnough LT, Price TH, Rudnick S, Soegiarso RW: Preoperative red blood cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion 1992;32:441-445.
15. Toy PTLC, Kaplan EP, McVay PA, Lee SJ, Strauss RG, Stehling LC: Blood loss and replacement in total hip arthroplasty: a multi-center study. Transfusion 1992;32:63-67.
16. Goodnough LT, Vizmeg K, Macus RE: Blood lost and transfused in patients undergoing elective orthopedic operations. Surg Gynecol Obstet 1993;176:235-238.
17. Monk TG, Goodnough LT, Brecher ME, Colberg JW, Andriole GL, Catalona WJ: A prospective randomized comparison of three blood conservation strategies for radical prostatectomy. Anesthesiology 1999;91:24-33.
18. Expert Working Group: Guidelines for red blood cell and plasma transfusion for adults and children. CMAJ 1997;156(suppl 11):S1-S24.
19. Ersleu AJ: Erythropoietin. N Engl J Med 1991;324:1339-1344.
20. Goodnough LT, Shander A, Brecher ME: Transfusion medicine: looking to the future. Lancet 2003;361:161-169.
21. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, Engert A: Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 2004;3:CD003407.
22. Finelli PF, Carley MD: Cerebral venous thrombosis associated with epoetin alfa therapy. Arch Neurol 2000;57:260-262.
23. Stasi R, Amadori S, Littlewood TJ, Terzoli E, Newland AC, Provan D: Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. Oncologist 2005;10:539-554.